Statement: the primary trial and the secondary trial both reported cases of sepsis in their patients.
Primary_evidence: Adverse Events 1:   Total: 11/50 (22.00%)   Anemia 3/50 (6.00%)   Febrile neutropenia 1/50 (2.00%)   Arrythmia 1/50 (2.00%)   Ileus 1/50 (2.00%)   Nausea 1/50 (2.00%)   Pain-Abdominal 1/50 (2.00%)   Vomiting 1/50 (2.00%)   Bronchial infection 1/50 (2.00%)   Sepsis 1/50 (2.00%)   Neutropenia 2/50 (4.00%)   Platelet count decreased 1/50 (2.00%)   Dehydration 1/50 (2.00%)   Arthralgia 1/50 (2.00%)
Secondary_evidence: Adverse Events 1:   Total: 20/101 (19.80%)   Neutropenia * 2/101 (1.98%)   Febrile neutropenia * 1/101 (0.99%)   Pericardial effusion * 2/101 (1.98%)   Abdominal distension * 1/101 (0.99%)   Abdominal pain * 1/101 (0.99%)   Ascites * 1/101 (0.99%)   Gastritis * 1/101 (0.99%)   Asthenia * 1/101 (0.99%)   Pyrexia * 1/101 (0.99%)   Pneumonia * 1/101 (0.99%)   Pseudomonal sepsis * 1/101 (0.99%)